Karyopharm Therapeutics KPTI
NASDAQ KPTI
$0.44 +0.08 (+21.56%)
As of: Oct 21, 2026 · 3:59 PM EDT

Karyopharm Therapeutics (KPTI) Short term Debt (2025 - 2026)

Updated

Karyopharm Therapeutics (KPTI) posted Short term Debt of $40.31 million for Q2 2026, up 544.9% from $6.25 million a year earlier.

Analysis

Karyopharm Therapeutics (KPTI) Short term Debt (2025 - 2026) Analysis & Trends

At the end of FY2025, Karyopharm Therapeutics' Short term Debt came in at $21.01 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Karyopharm Therapeutics 12.16 Mn -214.27 Mn 32.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 40.31 Mn
Dec 31, 2025 21.01 Mn
Sep 30, 2025 12.50 Mn
Jun 30, 2025 6.25 Mn
API Access

Karyopharm Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=KPTI&period=max&api_key=YOUR_API_KEY